The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Clinical trial NCT04876651 · TERMINATED
Trial details
- NCT number
- NCT04876651
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-29
- Primary completion
- 2025-07-01
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.